Aligos Therapeutics Q1 Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: seekingalpha
- Strong Earnings Report: Aligos Therapeutics reported a Q1 GAAP EPS of -$2.21, beating expectations by $0.04, indicating an improvement in financial performance that may boost investor confidence.
- Significant Revenue Growth: The company achieved revenue of $2.83M, representing an 812.9% year-over-year increase, exceeding expectations by $2.5M, which highlights strong product demand and significant future growth potential.
- Cash Flow Status: As of March 31, 2026, cash, cash equivalents, and investments totaled $54.9 million, down from $77.8 million as of December 31, 2025; however, this is expected to fund operations into Q4 2026, ensuring financial sustainability.
- Strategic Partnership Opportunity: The anticipated $25M upfront payment from the Amoytop Greater China licensing deal is expected to provide additional funding support, further advancing the company's efforts in hepatitis B drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGS
Wall Street analysts forecast ALGS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.790
Low
20.00
Averages
81.67
High
175.00
Current: 5.790
Low
20.00
Averages
81.67
High
175.00
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aligos Therapeutics Reports Positive Data on Pevifoscorvir Sodium
- Clinical Trial Results: Aligos Therapeutics presented ten positive data sets on Pevifoscorvir sodium for chronic hepatitis B at the 2026 EASL congress, indicating significant antiviral activity by reducing the cccDNA reservoir, potentially offering new treatment options for chronic HBV patients.
- Efficacy Observations: Untreated HBeAg+ patients who completed 96 weeks of Pevifoscorvir sodium monotherapy showed significant decreases in HBV and HBV RNA levels during a 24-week follow-up, suggesting the drug's potential for functional cure when combined with antiviral therapies.
- Combination Therapy Exploration: HBsAg+ patients on Pevifoscorvir sodium had HBV levels drop below 3000 IU/ml, indicating that combining it with the antisense oligonucleotide ALG-170675, developed with partner Amoytop, may yield improved therapeutic outcomes, further advancing the company's strategic positioning in chronic hepatitis B treatment.
- New Drug Development Directions: Aligos is also exploring ASO candidates for hepatitis delta virus and a THR-Beta agonist for metabolic dysfunction-associated steatohepatitis, showcasing the company's diversified research strategy in liver disease treatment.
See More
Aligos Announces Ten Abstracts Accepted at EASL Congress 2026
- Research Presentation: Aligos Therapeutics announced ten abstracts accepted for presentation at the 2026 European Association for the Study of the Liver Congress, covering chronic hepatitis B and metabolic dysfunction-associated steatohepatitis, showcasing its R&D capabilities and potentially enhancing its reputation in the biopharmaceutical industry.
- Therapeutic Potential: Notably, Pevifoscorvir sodium demonstrated significant antiviral activity in untreated HBeAg-positive chronic hepatitis B patients, positioning it as a potential first/best-in-class small molecule CAM-E, which could further strengthen the company's competitive edge in the liver disease treatment market.
- Clinical Research Progress: Aligos's ALG-001075 exhibited potent in vitro antiviral properties, likely providing new treatment options for chronic hepatitis B, thereby enhancing the company's clinical-stage pipeline to address high unmet medical needs.
- Forward-Looking Outlook: Participation in this congress not only highlights Aligos's research achievements but may also attract investor interest, boosting market confidence in its future clinical trials and product development, potentially leading to increased capital inflow for the company.
See More
Aligos Therapeutics Q1 Earnings Beat Expectations
- Strong Earnings Report: Aligos Therapeutics reported a Q1 GAAP EPS of -$2.21, beating expectations by $0.04, indicating an improvement in financial performance that may boost investor confidence.
- Significant Revenue Growth: The company achieved revenue of $2.83M, representing an 812.9% year-over-year increase, exceeding expectations by $2.5M, which highlights strong product demand and significant future growth potential.
- Cash Flow Status: As of March 31, 2026, cash, cash equivalents, and investments totaled $54.9 million, down from $77.8 million as of December 31, 2025; however, this is expected to fund operations into Q4 2026, ensuring financial sustainability.
- Strategic Partnership Opportunity: The anticipated $25M upfront payment from the Amoytop Greater China licensing deal is expected to provide additional funding support, further advancing the company's efforts in hepatitis B drug development.
See More
Aligos Therapeutics Grants Stock Options to New Employees
- Stock Options Granted: Aligos Therapeutics has granted 10,700 stock options to new employees under Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent and supporting the company's advancement in therapies for liver and viral diseases.
- Incentive Plan Details: The non-qualified stock options have an exercise price equal to the closing price on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments, contingent on continued employment.
- Market Performance: Over the past year, ALGS shares have traded between $4.20 and $13.69, currently priced at $6.53, reflecting a 6.49% increase, indicating positive market sentiment towards the company's prospects.
- Strategic Implications: The stock option grants not only enhance employee retention but also demonstrate Aligos' commitment to advancing its pipeline targeting chronic hepatitis B, MASH, obesity, and coronaviruses.
See More
Aligos Grants 10,700 Stock Options to New Employees
- Stock Option Grant: Aligos Therapeutics granted 10,700 non-qualified stock options to new employees on April 22, 2026, aimed at attracting top talent and enhancing employee loyalty, thereby strengthening the company's competitive position in the biopharmaceutical sector.
- Grant Plan Context: The stock option grant was made under Aligos' 2024 Inducement Plan, which is exclusively used for awarding equity to individuals not previously employed by the company, complying with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: The exercise price for the granted stock options is set equal to the closing price of Aligos' common stock on the grant date, ensuring alignment of interests between new employees and shareholders, which promotes long-term value enhancement for the company.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, a structure designed to incentivize long-term employee retention and contributions to the company's ongoing growth.
See More
Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront
- Deal Details: Aligos has signed a licensing agreement with Xiamen Amoytop, receiving an upfront payment of $25 million and the potential to earn up to $420 million in milestone payments, highlighting the company's prospects in hepatitis B treatment.
- Market Impact: The agreement led to a nearly 20% surge in Aligos shares during pre-market trading, and if sustained, it would mark the largest intraday gain since May 12, 2025, reflecting investor optimism about the company's future.
- Funding Support: Aligos expects that this deal will allow its current cash and investments to support operations into the fourth quarter of 2026, ensuring sufficient funding for future R&D and commercialization efforts.
- Market Opportunity: The drug targets over 90 million chronic hepatitis B patients in Greater China, and the combination with Amoytop's PEGBING® could offer more personalized treatment options, further expanding market share.
See More
Aligos Therapeutics Reports Positive Data on Pevifoscorvir Sodium
- Clinical Trial Results: Aligos Therapeutics presented ten positive data sets on Pevifoscorvir sodium for chronic hepatitis B at the 2026 EASL congress, indicating significant antiviral activity by reducing the cccDNA reservoir, potentially offering new treatment options for chronic HBV patients.
- Efficacy Observations: Untreated HBeAg+ patients who completed 96 weeks of Pevifoscorvir sodium monotherapy showed significant decreases in HBV and HBV RNA levels during a 24-week follow-up, suggesting the drug's potential for functional cure when combined with antiviral therapies.
- Combination Therapy Exploration: HBsAg+ patients on Pevifoscorvir sodium had HBV levels drop below 3000 IU/ml, indicating that combining it with the antisense oligonucleotide ALG-170675, developed with partner Amoytop, may yield improved therapeutic outcomes, further advancing the company's strategic positioning in chronic hepatitis B treatment.
- New Drug Development Directions: Aligos is also exploring ASO candidates for hepatitis delta virus and a THR-Beta agonist for metabolic dysfunction-associated steatohepatitis, showcasing the company's diversified research strategy in liver disease treatment.
See More
Aligos Announces Ten Abstracts Accepted at EASL Congress 2026
- Research Presentation: Aligos Therapeutics announced ten abstracts accepted for presentation at the 2026 European Association for the Study of the Liver Congress, covering chronic hepatitis B and metabolic dysfunction-associated steatohepatitis, showcasing its R&D capabilities and potentially enhancing its reputation in the biopharmaceutical industry.
- Therapeutic Potential: Notably, Pevifoscorvir sodium demonstrated significant antiviral activity in untreated HBeAg-positive chronic hepatitis B patients, positioning it as a potential first/best-in-class small molecule CAM-E, which could further strengthen the company's competitive edge in the liver disease treatment market.
- Clinical Research Progress: Aligos's ALG-001075 exhibited potent in vitro antiviral properties, likely providing new treatment options for chronic hepatitis B, thereby enhancing the company's clinical-stage pipeline to address high unmet medical needs.
- Forward-Looking Outlook: Participation in this congress not only highlights Aligos's research achievements but may also attract investor interest, boosting market confidence in its future clinical trials and product development, potentially leading to increased capital inflow for the company.
See More
Aligos Therapeutics Q1 Earnings Beat Expectations
- Strong Earnings Report: Aligos Therapeutics reported a Q1 GAAP EPS of -$2.21, beating expectations by $0.04, indicating an improvement in financial performance that may boost investor confidence.
- Significant Revenue Growth: The company achieved revenue of $2.83M, representing an 812.9% year-over-year increase, exceeding expectations by $2.5M, which highlights strong product demand and significant future growth potential.
- Cash Flow Status: As of March 31, 2026, cash, cash equivalents, and investments totaled $54.9 million, down from $77.8 million as of December 31, 2025; however, this is expected to fund operations into Q4 2026, ensuring financial sustainability.
- Strategic Partnership Opportunity: The anticipated $25M upfront payment from the Amoytop Greater China licensing deal is expected to provide additional funding support, further advancing the company's efforts in hepatitis B drug development.
See More
Aligos Therapeutics Grants Stock Options to New Employees
- Stock Options Granted: Aligos Therapeutics has granted 10,700 stock options to new employees under Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent and supporting the company's advancement in therapies for liver and viral diseases.
- Incentive Plan Details: The non-qualified stock options have an exercise price equal to the closing price on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments, contingent on continued employment.
- Market Performance: Over the past year, ALGS shares have traded between $4.20 and $13.69, currently priced at $6.53, reflecting a 6.49% increase, indicating positive market sentiment towards the company's prospects.
- Strategic Implications: The stock option grants not only enhance employee retention but also demonstrate Aligos' commitment to advancing its pipeline targeting chronic hepatitis B, MASH, obesity, and coronaviruses.
See More
Aligos Grants 10,700 Stock Options to New Employees
- Stock Option Grant: Aligos Therapeutics granted 10,700 non-qualified stock options to new employees on April 22, 2026, aimed at attracting top talent and enhancing employee loyalty, thereby strengthening the company's competitive position in the biopharmaceutical sector.
- Grant Plan Context: The stock option grant was made under Aligos' 2024 Inducement Plan, which is exclusively used for awarding equity to individuals not previously employed by the company, complying with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Setting: The exercise price for the granted stock options is set equal to the closing price of Aligos' common stock on the grant date, ensuring alignment of interests between new employees and shareholders, which promotes long-term value enhancement for the company.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments, a structure designed to incentivize long-term employee retention and contributions to the company's ongoing growth.
See More
Aligos Licenses Hepatitis B Drug to Xiamen Amoytop, Secures $25M Upfront
- Deal Details: Aligos has signed a licensing agreement with Xiamen Amoytop, receiving an upfront payment of $25 million and the potential to earn up to $420 million in milestone payments, highlighting the company's prospects in hepatitis B treatment.
- Market Impact: The agreement led to a nearly 20% surge in Aligos shares during pre-market trading, and if sustained, it would mark the largest intraday gain since May 12, 2025, reflecting investor optimism about the company's future.
- Funding Support: Aligos expects that this deal will allow its current cash and investments to support operations into the fourth quarter of 2026, ensuring sufficient funding for future R&D and commercialization efforts.
- Market Opportunity: The drug targets over 90 million chronic hepatitis B patients in Greater China, and the combination with Amoytop's PEGBING® could offer more personalized treatment options, further expanding market share.
See More
